PIKA Rabies Vaccine
Vaccine
Evidence outlook · registrational
Rabies Prevention and Post-Exposure Prophylaxis: topline reported 2024-04-09
Its supporting mid-stage studies have completed. The sponsor reported topline results on 2024-04-09 (Pivotal Phase 3 interim analysis meets primary endpoints). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05667974 NCT05667974 · Rabies Prevention and Post-Exposure Prophylaxis Registry: NCT05667974 | 3 | Primary Immunogenicity (14 days post-vaccination); Primary Immunogenicity (14 days post-vaccination); Co-primary Safety(solicited AEs) (7 days after each vaccination.); Co-primary Safety(unsolicited AEs) (From day of first vaccination through 14 days after the last vaccination); Co-primary Safety(SAEs) (through study completion, an average of 1 year); Co-primary Safety (through study completion, an average of 1 year) 2024-03-22 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Rabies Prevention and Post-Exposure Prophylaxis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PIKA Rabies Vaccine: this drug | Phase 3 | Vaccine | Rabies virus antigens (poly I:C-based adjuvant) | not yet graded | No reviewed efficacy summary in this indication | |
| SP0087 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent